Liverpool, UK-based clinical stage drug development company Evgen Pharma has appointed Dr Hamina Patel as its chief medical officer.
She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade.
Dr Patel has spent more than 15 years in the industry, and in addition to J&J she has also worked at Celltech and Chugai.
Dr Stephen Franklin, Evgen Pharma’s CEO, said: “Hamina has an impressive track record at global pharmaceutical companies and a breadth of relevant clinical experience.
“Her appointment strengthens the core team at Evgen and will be of great value in the delivery of our upcoming phase II clinical trials in metastatic breast cancer and in subarachnoid haemorrhage, both of which are on track to begin this year.”
Evgen’s lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke and the firm is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.